Pharmacokinetics and Tissue Distribution of Galantamine and Galantamine-related Radioactivity after Single Intravenous and Oral Administration in the Rat

Arzneimittel-Forschung/Drug Research

Volumn 54, Issue 2, 2004, Pages 85-94

  Van Beijsterveldt, Ludy ^a,b   Geerts, Rita ^a   Verhaeghe, Tom ^a   Willems, Bart ^a   Bode, Wilhelmina ^a   Lavrijsen, Karel ^a   Meuldermans, Willem ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Acetylcholinesterase inhibitor; Alzheimer's disease; CAS 1953 04 4; Galantamine, pharmacokinetics, rat, tissue distribution

Indexed keywords

GALANTAMINE;

ADRENAL GLAND; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOROID PLEXUS; CONTROLLED STUDY; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HAIR LEVEL; DRUG HALF LIFE; DRUG SALIVA LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID SCINTILLATION COUNTING; MALE; MATERNAL BLOOD; NONHUMAN; PLACENTAL TRANSFER; RAT; RAT STRAIN; SINGLE DRUG DOSE; SPLEEN; STRAIN DIFFERENCE; TISSUE DISTRIBUTION; WHITE ADIPOSE TISSUE; WHOLE BODY AUTORADIOGRAPHY;

EID: 1342347955     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296941     Document Type: Article

References (15)

1. Schuh, F. T., Zum molekularen Wirkungsmechanismus von Galanthamin, einem Curare-Antagonisten. Anästhesist 25, 444 (1979)
2. Thomsen, T., Bickel, U., Fischer, J. P. et al., Galanthamine hydrobromide in a long-term treatment of Alzheimer's disease. Dementia 1, 46 (1990)
3. Maelicke, A., Samochocki, M., Jostock, R. et al., Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol. Psychiat. 49, 279 (2001)
4. Bartus, R. T., Dean, R. L., Beer, B. et al., The cholinergic hypothesis of geriatric memory dysfunction. Science 217, 408 (1982)
5. Raskind, M. A., Peskind, E. R., Wessel, T. et al., Galantamine in AD. A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 54, 2261 (2000)
6. Tariot, P. N., Solomon, P. R., Morris, J. C. et al., A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 54, 2269 (2000)
7. Wilcock, G. K., Lilienfield, S., Gaens, E., Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. Br. Med. J. 321, 1445 (2000)
8. Wilkinson, D., Murray, J., Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease. Galantamine Research Group. Int. J. Geriatr. Psychiatry 16, 852 (2001)
9. 14C-and stable-isotope labelled galantamine. J. Labelled Compounds Radiopharm. 45, 841 (2002)
10. Ullberg, S., Studies on the distribution and fate of 35S-labelled benzylpenicillin in the body. Acta Radiol. Suppl. 118, 1 (1954)
11. Gibaldi, M., Perrier, D., Pharmacokinetics, pp. 199-219. Marcel Dekker Inc., New York - Basel (1982).
12. User's Guide for WinNonlin™ Professional. Scientific Consulting Inc., Cary, NC, USA (1997)
13. Mihailova, D., Yamboliev, I., Pharmacokinetics of galantamine hydrobromide (Nivalin®) following single intravenous and oral administration in rats. Pharmacology 32, 301 (1986)
14. Bickel, U., Thomsen, T., Fischer, J. P. et al., Pharmacokinetics, tissue distribution and cholinesterase inhibition in brain of mice. Neuropharmacology 30, 447 (1991)
15. Monbaliu, J., Verhaeghe, T., Willems, B. et al., Pharmacokinetics of galantamine, a cholinesterase-inhibitor, in several animal species. Arzneim.-Forsch./Drug Res. 53, 486 (2003)